Sickle cell drug pociredir tested for Long-Term safety in 50 patients
NCT ID NCT07401823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of the drug pociredir in 50 adults with sickle cell disease who have already taken it and seen benefits in an earlier study. Participants will take pociredir once daily for up to 48 months. The main goal is to track side effects and other health changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pociredir (also called FTX-6058)
- What this could lead to
- If successful, this could show that pociredir is safe enough to use long-term for managing sickle cell disease, potentially reducing complications.
- What could go wrong
- This is a small, early-phase extension study with no comparison group, so results may not prove effectiveness. Long-term side effects are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Jacobi Medical Center
The Bronx, New York, 10461, United States
-
Our Lady of the Lake Hospital
Baton Rouge, Louisiana, 70808, United States
-
Queens Hospital Cancer Center
Jamaica, New York, 11432, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of Texas Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease